- Home
- STTK vs CRVS Comparison
STTK vs CRVS Comparison
Compare STTK & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- CRVS
- Stock Information
- Founded
- STTK 2016
- CRVS 2014
- Country
- STTK United States
- CRVS United States
- Employees
- STTK N/A
- CRVS N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- CRVS Health Care
- Exchange
- STTK Nasdaq
- CRVS Nasdaq
- Market Cap
- STTK 37.6M
- CRVS 305.4M
- IPO Year
- STTK 2020
- CRVS 2016
- Fundamental
- Price
- STTK $0.83
- CRVS $4.03
- Analyst Decision
- STTK Hold
- CRVS Strong Buy
- Analyst Count
- STTK 4
- CRVS 4
- Target Price
- STTK $3.00
- CRVS $15.00
- AVG Volume (30 Days)
- STTK 401.8K
- CRVS 1.2M
- Earning Date
- STTK 07-31-2025
- CRVS 08-05-2025
- Dividend Yield
- STTK N/A
- CRVS N/A
- EPS Growth
- STTK N/A
- CRVS N/A
- EPS
- STTK N/A
- CRVS N/A
- Revenue
- STTK $4,606,000.00
- CRVS N/A
- Revenue This Year
- STTK N/A
- CRVS N/A
- Revenue Next Year
- STTK N/A
- CRVS N/A
- P/E Ratio
- STTK N/A
- CRVS N/A
- Revenue Growth
- STTK 69.65
- CRVS N/A
- 52 Week Low
- STTK $0.69
- CRVS $1.75
- 52 Week High
- STTK $4.99
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- STTK 39.19
- CRVS 50.43
- Support Level
- STTK $0.77
- CRVS $3.55
- Resistance Level
- STTK $0.91
- CRVS $4.09
- Average True Range (ATR)
- STTK 0.08
- CRVS 0.31
- MACD
- STTK -0.02
- CRVS -0.03
- Stochastic Oscillator
- STTK 16.23
- CRVS 49.14
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).